DDInter1191 DDInter535
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255647,L44612]
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Methylprednisolone {u} (Compound) upregulates {v} (Gene) CEBPD
CEBPD {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Methylprednisolone {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Diazoxide
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) binds {v} (Gene) CA1
CA1 {u} (Gene) is bound by {v} (Compound) Diazoxide
Methylprednisolone {u} (Compound) upregulates {v} (Gene) CEBPD
CEBPD {u} (Gene) regulates {v} (Gene) DDX42
DDX42 {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Methylprednisolone {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Hydroflumethiazide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Methylprednisolone {u} (Compound) upregulates {v} (Gene) CEBPD
CEBPD {u} (Gene) is regulated by {v} (Gene) KDM5A
KDM5A {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrochlorothiazide
Hydrochlorothiazide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrochlorothiazide
Hydrochlorothiazide {u} (Compound) binds {v} (Gene) CA1
CA1 {u} (Gene) is bound by {v} (Compound) Diazoxide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Methylprednisolone (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Diazoxide (Compound)
Methylprednisolone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Diazoxide (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) binds CA1 (Gene) and CA1 (Gene) is bound by Diazoxide (Compound)
Methylprednisolone (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) regulates DDX42 (Gene) and DDX42 (Gene) is upregulated by Diazoxide (Compound)
Methylprednisolone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Methylprednisolone (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is regulated by KDM5A (Gene) and KDM5A (Gene) is upregulated by Diazoxide (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) binds CA1 (Gene) and CA1 (Gene) is bound by Diazoxide (Compound)